Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Interest & Investment Income (2022 - 2026)

Zentalis Pharmaceuticals has reported Interest & Investment Income over the past 5 years, most recently at $2.6 million for Q1 2026.

  • For Q1 2026, Interest & Investment Income rose 198.76% year-over-year to $2.6 million; the TTM value through Mar 2026 reached $21.5 million, up 277.43%, while the annual FY2025 figure was $16.2 million, 36.52% down from the prior year.
  • Interest & Investment Income for Q1 2026 was $2.6 million at Zentalis Pharmaceuticals, roughly flat from $2.6 million in the prior quarter.
  • Over five years, Interest & Investment Income peaked at $34.9 million in Q1 2024 and troughed at -$22.9 million in Q2 2024.
  • A 5-year average of $4.3 million and a median of $3.2 million in 2022 define the central range for Interest & Investment Income.
  • Biggest five-year swings in Interest & Investment Income: surged 949.76% in 2023 and later crashed 613.66% in 2024.
  • Year by year, Interest & Investment Income stood at $3.2 million in 2022, then skyrocketed by 111.88% to $6.8 million in 2023, then plummeted by 68.28% to $2.2 million in 2024, then increased by 20.58% to $2.6 million in 2025, then increased by 0.15% to $2.6 million in 2026.
  • Business Quant data shows Interest & Investment Income for ZNTL at $2.6 million in Q1 2026, $2.6 million in Q4 2025, and $7.0 million in Q3 2025.